{"id":"doxycycline-hyclate-enteric-coated-capsules","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea and vomiting"},{"rate":"3-10%","effect":"Photosensitivity"},{"rate":"1-5%","effect":"Esophageal irritation"},{"rate":"2-5%","effect":"Diarrhea"},{"rate":"1-3%","effect":"Vaginal candidiasis"}]},"_chembl":{"chemblId":"CHEMBL3989740","moleculeType":"Small molecule","molecularWeight":"1025.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxycycline works by blocking the attachment of aminoacyl-tRNA to the bacterial ribosome, preventing peptide chain elongation and ultimately inhibiting bacterial growth. The enteric-coated formulation delays release until the drug reaches the small intestine, reducing gastrointestinal irritation. This broad-spectrum antibiotic is effective against a wide range of gram-positive and gram-negative bacteria, as well as some atypical organisms.","oneSentence":"Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:34.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including respiratory tract infections, urinary tract infections, and skin infections"},{"name":"Acne vulgaris"},{"name":"Malaria prophylaxis"},{"name":"Lyme disease"}]},"trialDetails":[{"nctId":"NCT03342456","phase":"PHASE4","title":"The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2017-12-13","conditions":"Duodenal Ulcer Due to Helicobacter Pylori","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Doxycycline Hyclate Enteric-Coated Capsules","genericName":"Doxycycline Hyclate Enteric-Coated Capsules","companyName":"The Third Xiangya Hospital of Central South University","companyId":"the-third-xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Bacterial infections including respiratory tract infections, urinary tract infections, and skin infections, Acne vulgaris, Malaria prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}